Maa: Kanada
Kieli: englanti
Lähde: Health Canada
PINDOLOL
TEVA CANADA LIMITED
C07AA03
PINDOLOL
5MG
TABLET
PINDOLOL 5MG
ORAL
100/500
Prescription
BETA-ADRENERGIC BLOCKING AGENTS
Active ingredient group (AIG) number: 0112362001; AHFS:
APPROVED
2011-09-15
1 PRODUCT MONOGRAPH PR TEVA-PINDOLOL Pindolol 5 mg, 10 mg and 15 mg Tablets USP Antihypertensive/Antianginal Agent Teva Canada Limited Date of Revision: 30 Novopharm Court April 23, 2019 Toronto, Ontario Canada M1B 2K9 www.tevacanada.com Control No: 225972 2 NAME OF DRUG Pr TEVA-PINDOLOL Pindolol 5 mg, 10 mg and 15 mg Tablets USP THERAPEUTIC CLASSIFICATION Antihypertensive/Antianginal Agent ACTIONS TEVA-PINDOLOL (pindolol) is a β-adrenergic-receptor-blocking agent which possesses partial agonist activity (intrinsic sympathomimetic activity - I.S.A.). It is used in the treatment of hypertension and/or the prophylaxis of angina pectoris. Hypertension The mechanism of the antihypertensive effect of pindolol has not been established. Among the factors that may be involved are: a) competitive ability to antagonize catecholamine-induced tachycardia at the β-receptor sites in the heart, thus decreasing cardiac output b) a reduction in total peripheral resistance c) inhibition of the vasomotor centres d) inhibition of renin release by the kidneys Angina Pectoris The mechanism of the antianginal effect of pindolol has not been established. Pindolol may reduce the oxygen requirement of the heart at any level of effort by blocking catecholamine- induced increases in the heart rate, systolic blood pressure, and the velocity and extent of myocardial contraction. However, oxygen requirements may be increased by such actions as increases in left ventricular fibre length, end diastolic pressure and the systolic ejection period. When the net effect is beneficial in patients with angina, it manifests itself during exercise or stress by delaying the onset of pain and reducing the incidence and severity of anginal attacks. In man, orally-administered pindolol is rapidly and almost completely absorbed (≥ 95%) from the gastrointestinal tract. The mean absolute bioavailability after oral administration is about 87- 92%. Plasma levels of 10 to 30 nanogram/mL are associated with its therapeutic efficacy. Following single dose adminis Lue koko asiakirja